RS-2026-25503089

Discovery of AI-Driven Mitochondrial Inner Membrane-Stabilizing Lead Peptides and Their Development as MASH Therapeutics

Sungkyunkwan University

성균관대학교 SUNG KYUN KWAN UNIVERSITY

METABOLIC | **Lead**

Product Type	rProtein
Indication	Metabolic dysfunction-associated steatohepatitis (MASH)
Target	Mitochondria and cardiolipin (CL)
MoA(Mechanism of Action)	Peptide binds to CL and restore cristae of the inner mitochondrial membrane
Competitiveness	• **High CL affinity:** Exhibits a 300-fold higher binding affinity compared to the first-in-class drug, SS-31. • **Mitochondrial protection:** Preserves cristae structure and overall organelle morphology.
Development Stage	Lead
Route of Administration	S.C. and I.V.